Zlecone: ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe
PARIS and LONDON, March 4, 2011 - /PRNewswire-FirstCall/ - Bristol-Myers Squibb Company (http://www.bms.com)(NYSE: BMY) and AstraZeneca (http://www.astrazeneca.com) (NYSE: AZN) today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is a new once-daily 2.5 mg dose.
- 04.03.2011, 10:00
- Kategoria: Zdrowie i styl życia
- Źródło: PAP
